Immunovant (IMVT) Cash & Equivalents Growth (1y) (2020 - 2026)

Immunovant (IMVT) Cash & Equivalents Growth (1y) (2020 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash & Equiv. Growth (1y) (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 23.56%
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 23.05%
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn 71.81%
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 84.98%
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn 10.29%
7 Royalty Pharma 33.72 Bn 35.84 Bn - 28.50%
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 53.39%
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn -57.58%
10 Immunovant 8.63 Bn 7.83 Bn - 33.21%

Historic Data

Download Data
DateValue
Jun 30, 2026 33.21%
Mar 31, 2026 26.35%
Dec 31, 2025 165.42%
Sep 30, 2025 10.35%
Jun 30, 2025 6.95%
Mar 31, 2025 12.37%
Dec 31, 2024 -45.77%
Sep 30, 2024 75.21%
Jun 30, 2024 69.72%
Mar 31, 2024 68.74%
Dec 31, 2023 59.71%
Sep 30, 2023 -33.48%
Jun 30, 2023 -22.76%
Mar 31, 2023 -23.75%
Dec 31, 2022 -17.91%
Sep 30, 2022 -27.41%
Jun 30, 2022 12.72%
Dec 31, 2021 24.88%
Sep 30, 2021 25.80%
Jun 30, 2021 35.22%